Haystack Oncology, Rutgers Cancer Institute to test effectiveness of MRD assay in guiding post-surgery NSCLC treatment decisions

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.

September 19, 2025

Vol.51 No.34

Drugs & Targets

FDA grants Hernexeo Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC

FDA granted Breakthrough Therapy designation to Hernexeos (zongertinib tablets) for first-line treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations.

September 12, 2025

Vol.51 No.33

In Brief

Joseph Contessa appointed chair of radiation oncology at Rutgers Cancer Institute

Joseph Contessa was named chair of radiation oncology for Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, and Rutgers New Jersey Medical School. He will also serve as associate director for translational research at Rutgers Cancer Institute.

August 08, 2025

Vol.51 No.31

In Brief

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

Arjan Gower, a hematologist/oncologist at the UCLA Health Jonsson Comprehensive Cancer Center, received a $950,000 grant from the National Comprehensive Cancer Network and Taiho Oncology Inc. to help launch a multi-institutional clinical trial to test zipalertinib, an investigational drug that targets specific EGFR mutations, including Exon 20 insertions, which are known to drive cancer growth and resist standard treatments.

July 11, 2025

Vol.51 No.27

In Brief

RWJBarnabas Health, Rutgers open NJ’s first and only freestanding cancer hospital

RWJBarnabas Health and Rutgers Cancer Institute, the state’s only NCI-designated Comprehensive Cancer Center, have opened New Jersey’s first and only freestanding, fully comprehensive cancer hospital (The Cancer Letter, April 25, 2025).

May 16, 2025

Vol.51 No.19

Conversation with The Cancer Letter

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Over the past seven years, as Steven K. Libutti was designing the 12-story, $900-plus million cancer hospital in New Brunswick, NJ, he often thought of the functionality of the building that inspired it: Building 10, the NIH Clinical Center.

April 25, 2025

Vol.51 No.16

By Paul Goldberg

Haystack Oncology, Rutgers Cancer Institute to test effectiveness of MRD assay in guiding post-surgery NSCLC treatment decisions

YOU MAY BE INTERESTED IN

Libtayo + chemo shows significant improvement in OS for advanced NSCLC, phase III EMPOWER-Lung 3 trial shows

FDA grants Hernexeo Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC

Joseph Contessa appointed chair of radiation oncology at Rutgers Cancer Institute

Arjan Gower receives NCCN grant to study a targeted therapy for early-stage NSCLC with rare EGFR mutations

RWJBarnabas Health, Rutgers open NJ’s first and only freestanding cancer hospital

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Renew today!

Subscriber content

Never miss an issue!

Login